SCHEMBL2501646

SCHEMBL2501646

O=C(O)c1ccc(-c2cc(F)ccc2F)c(C(=O)O)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EIF4E P06730 2/20 0.47
TTR P02766 2/20 0.45
KDM4E B2RXH2 2/20 0.45
LMNA P02545 2/20 0.45
MEN1 O00255 1/20 0.45
USP2 O75604 1/20 0.45
ALDH1A1 P00352 1/20 0.45
DHFR P00374 1/20 0.45
CA1 P00915 1/20 0.45
CA2 P00918 1/20 0.45
ALB P02768 1/20 0.45
HMGB1 P09429 1/20 0.45
HPGD P15428 1/20 0.45
CXCL12 P48061 1/20 0.45
KMT2A Q03164 1/20 0.45
HIF1A Q16665 1/20 0.45
SLC22A6 Q4U2R8 1/20 0.45
ACMSD Q8TDX5 1/20 0.45
HSD17B10 Q99714 1/20 0.45
PTGER1 P34995 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2500109 0.85 RAB9A (0.44) KDM4ELMNAMEN1ALDH1A1HPGD
SCHEMBL12193907 0.82 MAPK14 (0.51) KDM4ELMNAMEN1ALDH1A1KMT2A
SCHEMBL141961 0.82 KDM4E (0.55) TTRKDM4ECA1CA2KMT2A
SCHEMBL2313544 0.81 TTR (0.51) EIF4ETTRKDM4EKMT2AACMSD
SCHEMBL2313208 0.80 KDM4E (0.54) KDM4ELMNAMEN1ALDH1A1CA1
Hydrochloric Acid SCHEMBL28949814 0.80 KDM4E (0.53) TTRKDM4ECA1CA2KMT2A
SCHEMBL22190040 0.80 KEAP1 (0.63) EIF4ETTRKDM4ELMNAMEN1
SCHEMBL336060 0.78 KDM4E (0.52) TTRKDM4ELMNAMEN1ALDH1A1
SCHEMBL1222849 0.77 BCL2L1 (0.62) TTRKDM4ELMNAMEN1USP2
SCHEMBL20601776 0.76 ACMSD (0.53) EIF4ETTRKDM4ELMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8030354-B2 2-(5,5-Dimethylcyclopent-1-enyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane; metabolic disorders such as type II diabetes AMGEN INC. (US) 2011-10-04 US disclosed
US-20090137561-A1 Substituted biphenyl GPR40 modulators AMGEN INC. (US) 2009-05-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090137561-A1 Substituted biphenyl GPR40 modulators GPR119, GPR65, GPR55 EIF4E 3284/4885TTR 3698/4885KDM4E 2559/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.